Cargando…
Experience and Perspectives in the US on the Evolving Treatment Landscape in Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disorder that, until recently, was the most common inherited cause of infant mortality. Since 2016, three disease-modifying therapies have emerged, nusinersen, onasemnogene abeparvovec-xioi, and risdiplam, leading to a transformation...
Autores principales: | Ramos-Platt, Leigh, Elman, Lauren, Shieh, Perry B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491367/ https://www.ncbi.nlm.nih.gov/pubmed/36157294 http://dx.doi.org/10.2147/IJGM.S369021 |
Ejemplares similares
-
What Genetics Has Told Us and How It Can Inform Future Experiments for Spinal Muscular Atrophy, a Perspective
por: Blatnik, Anton J., et al.
Publicado: (2021) -
Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy
por: René, Charlotte A., et al.
Publicado: (2023) -
The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy
por: Sleigh, James N., et al.
Publicado: (2011) -
Autophagy inhibition: a new therapeutic target in spinal muscular atrophy
por: Piras, Antonio, et al.
Publicado: (2018) -
Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies
por: Angilletta, Ilaria, et al.
Publicado: (2023)